Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis.
about
American Society of Biomechanics Journal of Biomechanics Award 2013: cortical bone tissue mechanical quality and biological mechanisms possibly underlying atypical fractures.An Evaluative History of Bisphosphonate Drugs: Dual Physiologic Effects of Pyrophosphate as Inspiration for a Novel Pharmaceutical ClassThe transcription factor T-box 3 regulates colony-stimulating factor 1-dependent Jun dimerization protein 2 expression and plays an important role in osteoclastogenesisIncidence and Characteristics of Atypical Femoral Fractures: Clinical and Geometrical Data.UK clinical guideline for the prevention and treatment of osteoporosisBisphosphonate treatment for children with disabling conditions.Osteoporosis: a discussion on the past 5 years.Longitudinal Change in Trabecular Bone Score during and after Treatment of Osteoporosis in Postmenopausal Korean WomenThe potential economic benefits of improved postfracture care: a cost-effectiveness analysis of a fracture liaison service in the US health-care system.Long term bisphosphonate therapy & atypical femoral fractures: a word of caution.Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.Bisphosphonate-induced periprosthetic fracture: a cause of painful total hip arthroplasty.Male osteoporosis: clinical approach and management in family practice.Interleukin-1 receptor-associated kinase-4 (IRAK4) promotes inflammatory osteolysis by activating osteoclasts and inhibiting formation of foreign body giant cells.Risk of atypical femoral fracture during and after bisphosphonate use.Use of osteoporosis medications after hospitalization for hip fracture: a cross-national studyEffect of Stem Cell Therapy on Bone Mineral Density: A Meta-Analysis of Preclinical Studies in Animal Models of OsteoporosisSelective Estrogen Receptor Modulators Suppress Hif1α Protein Accumulation in Mouse Osteoclasts.Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancerShort-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.Research perspectives: The 2013 AAOS/ORS research symposium on Bone Quality and Fracture Prevention.Femur fracture classification in women with a history of breast cancer.Bisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday.Implant-delivered Alendronate Causes a Dose-dependent Response on Net Bone Formation Around Porous Titanium Implants in CaninesCompliance with established guidelines for the radiological reporting of atypical femoral fracturesBisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: sensitivity and trim and fill studies."Atypical" atypical femur fractures and use of bisphosphonates.Emerging drugs for osteoporosis.Myeloma bone disease: pathogenesis, current treatments and future targets.A rare case of bilateral proximal femoral insufficiency fractures after interlocking IM nailing for bilateral atypical femoral shaft fractures.Bisphosphonate drug holidays--when, why and for how long?Epidemiology and Postoperative Outcomes of Atypical Femoral Fractures in Older Adults: A Systematic Review.Evaluating Atypical Features of Femur Fractures: How Change in Radiological Criteria Influenced Incidence and Demography of Atypical Femur Fractures in a Community Setting.Impact of the U.S. Food and Drug Administration's Safety-Related Announcements on the Use of Bisphosphonates After Hip FractureLong-term radiographic follow-up of bisphosphonate-associated atypical femur fractures.The advantages of tomosynthesis for evaluating bisphosphonate-related atypical femur fractures compared to radiography.Atypical femoral fractures bilaterally in a patient receiving bisphosphonate: a case report.Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment.Insufficiency Fractures at Unusual Sites: A Case Series.Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.
P2860
Q27027254-4C4C6E7C-E71B-4662-A57D-B2C6BD52E1B7Q28077051-43F98CDD-94D4-440C-81C1-B4B95AE1D294Q28305297-A2180616-F706-4513-9BE8-2CAC4EDB0085Q31026858-B5CE281B-8ECF-4223-A196-E14A75A45EF6Q33581078-5AE4DC96-5117-4788-8BFC-0651D0A2703EQ33680621-61E8129A-5944-418E-B6EC-4D4A87DAEFF0Q33700265-EB972F18-83B5-4413-B1E3-56C1DBF45446Q33804839-BC088BE4-2417-42D5-95B6-8C8880909FA9Q34251696-9905DDC0-AF1F-49CC-AC59-04EF4F65A207Q34272165-99636D54-BEBB-455B-8ED5-C187451DFBE9Q34626680-C69033FC-73E5-4034-8DE2-DE64838BFF64Q34770435-6DE5138A-97B3-4573-9F22-9E19B0AA814BQ34929054-F61FE06E-4C21-4A14-B1C1-6DF6790DC8B6Q34958651-CA7B0975-2FD0-48C8-AD96-3335F73066C7Q35197628-49BF1280-7376-43D0-889F-0C5B9DCC05FAQ35554696-BB54192D-270B-43EC-A52F-A4311687B4C1Q35925142-E2C70D5D-7431-451C-9291-5F1A36FAE1EAQ36179411-F7842B74-F3B2-4B3B-83D4-D01839C11E14Q36345986-58470885-0B62-42EF-9929-F8181381F205Q36433566-7774F53C-5CE0-42E8-B68C-2B8268C787B0Q36473294-CADC126A-4B46-45BA-B691-299DA2FE7DA1Q36492212-47B9EF3C-8CC3-46A8-B8F6-CCD4216851CEQ36523054-03554209-52DC-4D0C-9052-3584D062C41DQ36746791-C3A6B9FF-B3C9-4DD8-B86A-101901DAE273Q37177831-CC6C4D6A-9BE1-48CD-ADA5-5F6721F9AE43Q37587913-DA8A77A3-7B4D-4509-A936-458461B66522Q37653262-58B3D961-333A-4654-8802-F284E0CB9F24Q38226342-B06B953D-17DC-4037-87A4-C1008AC6A920Q38246241-FE52E662-04DC-4681-8F34-0E32B5929137Q38425239-3B64383B-C4BF-4EE0-BB49-A2C92B450B97Q38617760-5EEBDE2F-B82A-4CE6-88D2-010CE5D58966Q39045046-BB4441D2-0C4C-4E11-98B3-2CF193C11C2BQ39450258-F4100AE4-DC37-4482-99B2-4A6BD15BCF38Q39926515-29E60CA0-4AA5-4A63-9FB2-4F71E09D76EAQ39994949-3E0230F7-28CA-4402-9BFF-C5C2156898D9Q40009832-A9419073-40CB-4F4E-A39A-ADD16AFFD630Q42113291-666592A4-7DC7-46AF-A439-4D363E2E9462Q47097588-F84200D8-1D27-48AF-A62D-114C78DFB755Q47137367-43E3282F-821E-4BFA-B649-03F7C0A4D25FQ47279165-D0E033F5-D6BE-4583-9FF8-9079F458465F
P2860
Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bisphosphonates and risk of su ...... atic review and meta-analysis.
@en
Bisphosphonates and risk of su ...... atic review and meta-analysis.
@nl
type
label
Bisphosphonates and risk of su ...... atic review and meta-analysis.
@en
Bisphosphonates and risk of su ...... atic review and meta-analysis.
@nl
prefLabel
Bisphosphonates and risk of su ...... atic review and meta-analysis.
@en
Bisphosphonates and risk of su ...... atic review and meta-analysis.
@nl
P2093
P2860
P356
P1476
Bisphosphonates and risk of su ...... atic review and meta-analysis.
@en
P2093
Daniel H Solomon
Lydia Gedmintas
Seoyoung C Kim
P2860
P304
P356
10.1002/JBMR.1893
P577
2013-08-01T00:00:00Z